Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow SOLENO THERAPEUTICS INC

Get SEC filing alerts via email and in your feed for SOLENO THERAPEUTICS INC

SLNO

SOLENO THERAPEUTICS INC

About SOLENO THERAPEUTICS INC

Soleno Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, notably Prader-Willi syndrome (PWS). Its lead product, DCCR, aims to reduce hyperphagia and behavioral symptoms by targeting physiological pathways involving appetite and fat regulation. The company advances its therapies through clinical trials, regulatory approvals, and targeted commercialization, addressing significant unmet medical needs in the rare disease market.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from SOLENO THERAPEUTICS INC

1
1
SOLENO THERAPEUTICS INC Soleno Therapeutics Reports $31.4M Net Income and $94.6M Revenue in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
SOLENO THERAPEUTICS INC Soleno Therapeutics Reports $190.4M Revenue and $20.9M Net Income in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
SOLENO THERAPEUTICS INC Soleno Therapeutics Reports $66M Product Revenue and $26M Net Income in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
SOLENO THERAPEUTICS INC Soleno Therapeutics Reports $32.7M Revenue from VYKAT XR Launch in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
SOLENO THERAPEUTICS INC Soleno Therapeutics Reports $43.8 Million Net Loss in Q1 2025 Amid VYKAT XR Launch

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
SOLENO THERAPEUTICS INC Soleno Therapeutics Reports $175.9 Million Net Loss and Expands Workforce in Annual Filing

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
SOLENO THERAPEUTICS INC Soleno Therapeutics Reports Significant Financial Changes, Net Losses Increase 673% in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments